Article Text

Download PDFPDF

Treatment of cytomegalovirus retinitis with ganciclovir (9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine (BW B759U).
  1. J Orellana,
  2. S A Teich,
  3. J S Winterkorn,
  4. U Mathur-Wagh,
  5. S Handwerger,
  6. H Schlamm,
  7. S C Malamud,
  8. S R Yancovitz,
  9. D M Cederberg and
  10. D S Mildvan
  1. Department of Ophthalmology, Beth Israel Medical Center, New York, New York 10003.


    Six patients (11 eyes) with virologically confirmed cytomegalovirus (CMV) retinitis involving the posterior pole of the eye were treated with a new drug, ganciclovir. Treatment with intravenous ganciclovir consistently halted progression of retinitis and produced improvement in measures of visual function. However, within three weeks after cessation of therapy renewed CMV activity and worsening of visual function were observed in most cases. Maintenance therapy with ganciclovir extended the period of remission from CMV retinitis.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.